

Resource Summary Report

Generated by [dkNET](#) on Jul 30, 2026

Bcl-2 (100)

RRID:AB_626733

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-509, RRID:AB_626733

Antibody Information

URL: http://antibodyregistry.org/AB_626733

Proper Citation: Santa Cruz Biotechnology Cat# sc-509, RRID:AB_626733

Target Antigen: Bcl-2 (100)

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: WB, IP, IF, IHC(P), FCM; Immunofluorescence; Immunohistochemistry; Immunocytochemistry; Flow Cytometry; Western Blot; Immunoprecipitation

Antibody Name: Bcl-2 (100)

Description: This monoclonal targets Bcl-2 (100)

Target Organism: human

Antibody ID: AB_626733

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-509

Record Creation Time: 20250819T231501+0000

Record Last Update: 20250820T044529+0000

Ratings and Alerts

No rating or validation information has been found for Bcl-2 (100).

No alerts have been found for Bcl-2 (100).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Fiskus W, et al. (2025) Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. *Blood*, 145(6), 612.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. *iScience*, 28(6), 112584.

van Gemert F, et al. (2024) ADARp150 counteracts whole genome duplication. *Nucleic acids research*, 52(17), 10370.

Meril S, et al. (2024) Loss-of-function cancer-linked mutations in the EIF4G2 non-canonical translation initiation factor. *Life science alliance*, 7(3).

Ming Z, et al. (2023) IFN- γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics. *The Journal of investigative dermatology*, 143(7), 1246.

Fiskus W, et al. (2022) Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). *Blood cancer journal*, 12(1), 5.

Wiede F, et al. (2022) PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. *Cancer discovery*, 12(3), 752.

Abo El Gheit RE, et al. (2022) Melatonin epigenetic potential on testicular functions and fertility profile in varicocele rat model is mediated by silent information regulator 1. *British journal of pharmacology*, 179(13), 3363.

Prew MS, et al. (2022) MCL-1 is a master regulator of cancer dependency on fatty acid oxidation. *Cell reports*, 41(1), 111445.

Lafferty A, et al. (2021) Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(21), 5979.

Campos JC, et al. (2020) β 2 -adrenoceptor activation improves skeletal muscle autophagy in neurogenic myopathy. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 34(4), 5628.

Mohankumar K, et al. (2020) Bis-Indole-Derived Nuclear Receptor 4A1 (NR4A1, Nur77) Ligands as Inhibitors of Endometriosis. *Endocrinology*, 161(4).

Elkholi R, et al. (2019) MDM2 Integrates Cellular Respiration and Apoptotic Signaling through NDUFS1 and the Mitochondrial Network. *Molecular cell*, 74(3), 452.

Fiskus W, et al. (2019) Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. *Blood cancer journal*, 9(2), 4.

Benedict B, et al. (2018) Loss of p53 suppresses replication-stress-induced DNA breakage in G1/S checkpoint deficient cells. *eLife*, 7.

Muñoz-Moreno L, et al. (2018) Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer. *The Prostate*, 78(12), 915.